Heartseed株式会社 Logo

Heartseed株式会社

Develops iPSC-derived cell therapies to regenerate heart tissue for heart failure.

219A | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
港区芝浦1丁目2番3号シーバンスS館5階
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Heartseed Inc. is a clinical-stage biotechnology company specializing in regenerative medicine for cardiac diseases. Founded in 2015 as a spin-off from Keio University, the company develops iPSC-derived cell therapies for severe heart failure. Its core strategy is "remuscularization," a novel approach to regenerate damaged heart tissue by transplanting highly purified cardiomyocyte spheroids. The lead pipeline product, HS-001, is an allogeneic iPSC-derived cardiomyocyte therapy administered via intramyocardial injection for patients with heart failure with reduced ejection fraction (HFrEF). Heartseed aims to provide a fundamental treatment for conditions where heart transplantation was previously the only curative option. The company also conducts research on next-generation therapies using autologous and HLA-edited iPSCs to minimize immune rejection.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Heartseed株式会社 and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-19 09:00
Regulatory News Service
臨時報告書
Japanese 19.9 KB
2025-06-12 08:30
Regulatory News Service
確認書
Japanese 8.0 KB
2025-06-12 08:30
Interim Report
半期報告書-第10期(2024/11/01-2025/12/31)
Japanese 143.9 KB
2025-01-27 02:01
Regulatory News Service
臨時報告書
Japanese 21.3 KB
2025-01-27 02:01
Regulatory News Service
確認書
Japanese 8.0 KB
2025-01-27 02:00
Annual Report
有価証券報告書-第9期(2023/11/01-2024/10/31)
Japanese 6.0 MB
2025-01-27 02:00
Regulatory News Service
内部統制報告書-第9期(2023/11/01-2024/10/31)
Japanese 21.1 KB
2024-07-22 08:18
Regulatory News Service
訂正有価証券届出書(新規公開時)
Japanese 4.6 MB
2024-07-11 08:00
Regulatory News Service
訂正有価証券届出書(新規公開時)
Japanese 4.6 MB
2024-06-26 08:00
Prospectus
有価証券届出書(新規公開時)
Japanese 9.0 MB

Automate Your Workflow. Get a real-time feed of all Heartseed株式会社 filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Heartseed株式会社 via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.